The essential A resident of Thuir (Pyrénées-Orientales) received a dose of the AstraZeneca vaccine from the suspect batch ABV5300. The latter was suspended in several European countries after bleeding disorders were reported in some vaccinated patients. During a press conference on Thursday, Health Minister Olivier Véran assured that there was no bottle of this suspicious batch in France.
His vaccination record is clear, Gérard received an injection of the AstraZeneca vaccine from the suspect batch ABV5300. The batch in question was withdrawn from circulation in five European countries (three Baltic states, Luxembourg and Austria) after the occurrence of bleeding disorders in vaccinated patients.
According to L’Indépendant, bottles of the suspicious batch were used in France, contrary to what Olivier Véran said during a press conference on Thursday 11 March. Gérard, 71, received his first dose of vaccine on Sunday March 7th at the Thuir Hospital Center (Pyrénées-Orientales). On that day, a “slap” operation was carried out in the hospital to speed up the vaccination campaign.
Also read: REPLAY. AstraZeneca vaccine suspended in several countries: Olivier Véran announces its continued use in France
Other affected patients
Time slots were cleared and residents of the ward eligible for vaccination were there. Since the campaign began, 17,000 people have received their first dose of AstraZeneca vaccine in the Pyrenees-Orientals, including 6,000 doses dispensed on March 3 on the same day as the bottle from the contaminated batch.
It is currently unknown how many vials from this batch were used. In addition to Gerard, at least nine other people received a dose from the same vial, with each vial of AstraZeneca vaccine containing ten.
More information is available on the L’Indépendant website.
What pharmacovigilance reports say
In its weekly pharmavigilance report, the French Medicines Agency discusses the fate of this famous ABV5300 batch. “Although there has only been one case in France so far, given the severity and existence of Austrian cases of multiple thromboses that lead to the suspension of batch ABV5300, we are of the opinion that there is a signal in cases of coagulopathies,” she explains in a Report released on Friday March 12th.
However, when carefully analyzing the follow-up of patients who have already been vaccinated with AstraZeneca, including this batch of ABV5300, it is reassuring: “Among these cases, there are no cases of death, no cases of start-up. Game is life – threatened and there are no cases of thrombosis and thrombocytopenia. “In addition, after preliminary investigation, the Medicines Agency has currently found no link between the injection of the vaccine and the only serious case of thrombosis in France.
As a reminder, as of Friday March 12th, only four European countries had completely stopped using the AstraZeneca vaccine as a precaution: Denmark, Norway, Iceland and Bulgaria.